Midazolam is a potent benzodiazepine derivative with sedative, hypnotic, anticonvulsant, muscle-relaxant and anxiolytic activities. It undergoes oxidative metabolism catalyzed almost exclusively by the CYP3A subfamily to a major metabolite, 1'-hydroxymidazolam, which is equipotent to midazolam. 1'-Hydroxymidazolam is subject to glucuronidation followed by renal excretion. To date, the glucuronidation of 1'-hydroxymidazolam has not been evaluated in detail. In the current study, we identified an unreported quaternary N-glucuronide, as well as the known O-glucuronide, from incubations of 1'-hydroxymidazolam in human liver microsomes enriched with UDPGA.
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Midazolam is a potent benzodiazepine derivative with sedative, hypnotic, anticonvulsant, muscle-relaxant and anxiolytic activities. It is widely used in the clinic for induction of anesthesia and for sedation of patients who are artificially ventilated in intensive care units (Dundee et al. 1984) . Midazolam is rapidly eliminated from the body, almost exclusively by metabolism (Heizmann, et al. 1983) . It undergoes oxidative metabolism mainly catalyzed by the CYP3A subfamily to a major metabolite, 1'-hydroxymidazolam, which is equipotent to midazolam, and two minor metabolites, 4-hydroxymidazolam and 1',4-dihydroxymidazolam, which are quantitatively unimportant (Dundee et al. 1984) . 1'-Hydroxymidazolam is subject to further glucuronidation, followed by renal excretion. In humans, urinary recovery of 1'-hydroxymidazolam glucuronide accounted for 60-70% of an administered dose of [ 14 C]midazolam (Heizmann and Ziegler, 1981) . It has been reported that elevated serum levels of 1'-hydroxymidazolam glucuronide were found in patients with renal failure after administration of midazolam, and may account for the prolonged sedation observed in those patients (Bauer et al. 1995; Hirata et al. 2003) .
Glucuronidation represents one of the major Phase II conjugation reactions in the conversion of both exogenous and endogenous compounds to polar and water-soluble metabolites that can be eliminated from the body in urine or bile (Sipes and Gandolfi, 1991) . The reaction is catalyzed by a family of enzymes, UDP-glucuronosyltransferases (UGTs), which transfer glucuronic acid from UDP-glucuronic acid to the aglycone substrate. UGTs comprise of two subfamilies, UGT1 and UGT2. The substrate specificity of individual UGTs has been partially characterized. UGT subfamily 1 is responsible for This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on November 12, 2007 as DOI: 10.1124 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org Downloaded from glucuronidation of bilirubin, amines, planar and bulky phenols, whereas subfamily 2 enzymes catalyze glucuronidation of a diverse chemical base including steroids, bile acids, and opioids (King et al. 2000) .
To date the glucuronidation of 1'-hydroxymidazolam has not been studied in detail. In the literature, 1'-hydroxymidazolam glucuronide is often assumed to be an O-glucuronide.
In the current study, we have identified an unreported quaternary N-glucuronide, as well as the known O-glucuronide, from incubations of 1'-hydroxymidazolam in human liver microsomes enriched with UDPGA. Further studies were conducted to determine the isozymes responsible for the formation of N-and O-glucuronic acid conjugates of 1'-hydroxymidazolam in human liver microsomes.
Enzyme Kinetics Analysis. The apparent kinetic parameters K m /S 50 , V max and n (Hill coefficient; where appropriate) were calculated using nonlinear regression analysis (Sigma Plot, Systat Software Inc., San Jose, CA). Each set of data was fitted to both the Michaelis-Menten and the Hill equations. The quality of fit to a particular model was determined by evaluation of three criteria that are listed in decreasing order of importance: 1) the randomness of the residuals; 2) the size of the sum of the square of the residuals; and 3) the standard error of the parameter estimates (Soars et al. 2003) . The maximal intrinsic clearance due to autoactivation kinetics was calculated based on the following equation (Houston and Kenworthy, 2000) :
Inhibition with Chemical Inhibitors of UGTs.
The incubations of 1'-hydroxymidazolam at a substrate concentration close to the apparent K m /S 50 values (25 or 50 µM) were conducted in human liver microsomes, as described above, in the presence of diclofenac (9.3 to 500 µM) or hecogenin (2.5 to 400 µM). The reaction was allowed to proceed at 37˚C for 45 min, and was terminated with ice-cold acetonitrile containing 0.2% formic acid and phenolphthalein-β-D-glucuronide as the internal standard. The assay was performed in duplicate. Samples were centrifuged prior to LC-MS/MS analysis. Similar inhibition studies were conducted using recombinant UGT1A4 or 2B4/2B7 in the presence of hecogenin or diclofenac (0.4 to 100 µM), respectively. The IC 50 values were calculated using nonlinear regression analysis (KaleidaGraph by Synergy Software).
This article has not been copyedited and formatted. The final version may differ from this version. Only Glu-A was detected in incubations with rat liver microsomes (Fig. 1a) . Subsequent product ion scan at m/z 518 revealed different fragmentation patterns for these two glucuronides. A fragment ion at m/z 324 (loss of 194 Da) was the most prominent fragment observed with Glu-A; while a fragment ion at m/z 342 (loss of 176 Da) was the major ion for Glu-B (Fig. 1a) .
LC-MS/MS
When midazolam was incubated with liver microsomes enriched with UDPGA, one glucuronide (Glu; m/z 502) was detected in human liver microsomes, but not in rat liver microsomes (Fig. 1b) .
Structure identification of 1'-hydroxymidazolam glucuronides (Glu-A and Glu-B) by NMR.
Glu-A and Glu-B were isolated and their structures were determined by comparing their NMR spectra to that of 1′-hydroxymidazolam (Fig. 2a) . The major glucuronide (Glu-A) was confirmed to be the O-glucuronide (Fig. 2c) . The minor (Glu-B), a hitherto unknown glucuronide, was shown to be a quaternary N-glucuronide (Fig. 2b) .
The distinction between O-vs. N-glucuronide structures was evident from both 1 H and pmol/mg/min (Fig. 4) . Thus, the maximal intrinsic clearance for the O-glucuronidation was ~9-fold higher than that for the N-glucuronidation. No metabolism was observed with other UGT enzymes (the limit of assay sensitivity was ~0.01 µM). The kinetic parameters of the glucuronidation catalyzed by UGT2B4, 2B7
Glucuronidation
and 1A4 are presented in Table 1 (Fig. 5a ). This inhibitory effect of hecogenin was further confirmed using recombinant UGT1A4 (IC 50 value = 0.77 µM) (Fig. 5b) .
Diclofenac, on the other hand, had a greater inhibitory effect on the formation of Oglucuronide than on the formation of N-glucuronide by human liver microsomes (IC 50 values: 16 vs 151 µM) (Fig. 6a) . Further inhibition studies with recombinant UGT isozymes indicated that diclofenac exhibited similar inhibitory effect toward UGT2B4-and 2B7-mediated O-glucuronidation of 1′-hydroxymidazolam, with IC 50 values of 7.4 and 17.2 µM, respectively (Fig. 6b ).
This article has not been copyedited and formatted. The final version may differ from this version. In a separate study, where midazolam was used as the substrate, an analogous Nglucuronide also was detected in human liver microsomal incubations in the presence of UDPGA (Fig 1b) . It was reported previously that a quaternary N-glucuronide of midazolam was detected from human liver preparations in vitro, but no structure hydroxymidazolam N-glucuronide presented here, it is reasonable to assume that glucuronic acid was conjugated to midazolam at the same N-2 position.
The O-and N-glucuronidation of 1'-hydroxymidazolam in human liver microsomes exhibited non-Michaelis-Menten kinetics consistent with autoactivation, which has been reported for in vitro glucuronidation of several substrates (Soars et al. 2003; Fisher et al. 2000) as well as in vivo (Wong et al. 2007 ). The mechanism of autoactivation kinetics observed for UGTs is currently unknown.
In vitro incubations with twelve different recombinant human UGT isoforms showed that UGT1A4 was the only isoform catalyzing N-glucuronidation of 1'-hydroxymidazolam. UGT1A4 has been identified in human liver and stomach. It is a major UGT isoform involved in the glucuronidation of many tertiary amines (Green and Tephly 1996; King et al. 2000) . But there is no UGT1A4 ortholog in rat tissues (King et al. 2000) . Accordingly, when 1'-hydroxymidazolam was incubated with rat liver microsomes enriched with UDPGA, only the O-glucuronide (Glu-A) but not the Nglucuronide (Glu-B) was detected, consistent with the observation that UGT1A4 is the only UGT isoform catalyzing the N-glucuronidation. Similar studies with midazolam also showed that an analogous N-glucuronide formed in human liver microsomes was not observed in rat liver microsomes enriched with UDPGA, and only UGT1A4 was able to catalyze the formation of midazolam N-glucuronide.
Hecogenin is a known substrate and a selective inhibitor of UGT1A4 (Green and Tephly 1996; Al-Zoughool and Talaska 2006; Uchaipichat et al. 2006 ). In the current Our study demonstrated that UGT2B4 and 2B7 are the two isoforms responsible for the in vitro formation of 1'-hydroxymidazolam O-glucuronide in human liver microsomes.
UGT2B7 is a very important human UGT isoform in that it appears to be expressed in many tissues besides liver, and it catalyzes the glucuronidation of a wide range of xenobiotics, including polycyclic aromatic hydrocarbons, phenols, opioids, aliphatic alcohols, carboxylic acids, tetrazoles (King et al. 2000) . Recently, UGT2B7 was reported to catalyze the N-glucuronidation of an amide and a primary amine (Zhang et al. 2004; Staines et al. 2004 ). In contrast, UGT2B4 catalyzes only a limited number of substrates, and the data so far are not consistent among different labs. For example, the glucuronidation of hyodeoxycholic acid was reported to be catalyzed by UGT2B4; yet in another study, UGT2B4 showed no activity for hyodeoxycholic acid (King et al. 2000) .
The best substrate for this isoform has yet to be identified. Diclofenac is a substrate of UGT2B7, and also inhibits the glucuronidation of dihydrocodeine and morphine catalyzed by UGT2B7 (King et al 2001) . In the present study, diclofenac selectively of certain UGT isoforms could be very useful when evaluating drug-drug interaction potential of a given compound at the UGT level. For this purpose, 1'-hydroxymidazolam could be used as an in vitro probe substrate for UGT1A4 and UGT2B4/2B7 by monitoring the formation of N-and O-glucuronide, respectively. In clinical drug-drug interaction studies, midazolam is often used as a probe substrate for CYP3A (Thummel et al. 1994a; Thummel et al. 1994b; Huang et al 2007) . The exposure to midazolam, if altered, will inform on the potential of an investigational drug as a perpetrator of CYP3A.
On the other hand, given that the levels of 1'-hydroxymidazolam in plasma are the result of formation by CYP3A and subsequent metabolism to glucuronides by UGTs, by monitoring plasma concentration of 1'-hydroxymidazolam from the same study, we may be able to get additional insights into the potential of the investigational drug to affect selected UGT isoforms (UGT1A4, 2B4, 2B7), assuming the exposure to midazolam is not altered.
In summary, we have demonstrated, for the first time, the formation of a quaternary 
